JP2013533867A - ケロイド治療 - Google Patents
ケロイド治療 Download PDFInfo
- Publication number
- JP2013533867A JP2013533867A JP2013516930A JP2013516930A JP2013533867A JP 2013533867 A JP2013533867 A JP 2013533867A JP 2013516930 A JP2013516930 A JP 2013516930A JP 2013516930 A JP2013516930 A JP 2013516930A JP 2013533867 A JP2013533867 A JP 2013533867A
- Authority
- JP
- Japan
- Prior art keywords
- glutamine
- alanyl
- keloid
- scar
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010023330 Keloid scar Diseases 0.000 title claims abstract description 29
- 238000011282 treatment Methods 0.000 title description 13
- 208000002260 Keloid Diseases 0.000 title description 5
- 210000001117 keloid Anatomy 0.000 title description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims abstract description 18
- 229960002648 alanylglutamine Drugs 0.000 claims abstract description 17
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 238000011200 topical administration Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 23
- 238000009472 formulation Methods 0.000 abstract description 13
- 230000036573 scar formation Effects 0.000 abstract description 10
- 108010044940 alanylglutamine Proteins 0.000 abstract description 9
- 231100000241 scar Toxicity 0.000 abstract description 7
- 210000003491 skin Anatomy 0.000 abstract description 7
- 210000004207 dermis Anatomy 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 3
- 230000008591 skin barrier function Effects 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 230000037390 scarring Effects 0.000 abstract description 2
- 230000002500 effect on skin Effects 0.000 abstract 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 45
- 208000027418 Wounds and injury Diseases 0.000 description 16
- 206010052428 Wound Diseases 0.000 description 14
- 108010016626 Dipeptides Proteins 0.000 description 11
- 229930182816 L-glutamine Natural products 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 102000009123 Fibrin Human genes 0.000 description 9
- 108010073385 Fibrin Proteins 0.000 description 9
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 9
- 229950003499 fibrin Drugs 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 208000014674 injury Diseases 0.000 description 7
- 239000006071 cream Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000008733 trauma Effects 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000004303 peritoneum Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PNMUAGGSDZXTHX-BYPYZUCNSA-N Gly-Gln Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-BYPYZUCNSA-N 0.000 description 3
- 206010060932 Postoperative adhesion Diseases 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 108010010147 glycylglutamine Proteins 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 210000002747 omentum Anatomy 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010070245 Foreign body Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000021476 total parenteral nutrition Nutrition 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- MXCVHSXCXPHOLP-UHFFFAOYSA-N 4-oxo-6-propylchromene-2-carboxylic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=CC(CCC)=CC=C21 MXCVHSXCXPHOLP-UHFFFAOYSA-N 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014357 Electric shock Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 241001387976 Pera Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 206010041101 Small intestinal obstruction Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000001039 kidney glomerulus Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000004018 waxing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35905310P | 2010-06-28 | 2010-06-28 | |
| US61/359,053 | 2010-06-28 | ||
| PCT/CA2011/050396 WO2012000113A1 (en) | 2010-06-28 | 2011-06-28 | Keloid treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013533867A true JP2013533867A (ja) | 2013-08-29 |
| JP2013533867A5 JP2013533867A5 (OSRAM) | 2014-08-14 |
Family
ID=45401271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516930A Pending JP2013533867A (ja) | 2010-06-28 | 2011-06-28 | ケロイド治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20140005116A1 (OSRAM) |
| EP (1) | EP2585090A4 (OSRAM) |
| JP (1) | JP2013533867A (OSRAM) |
| KR (1) | KR20130089174A (OSRAM) |
| CN (1) | CN103002903B (OSRAM) |
| AU (1) | AU2011274224A1 (OSRAM) |
| BR (1) | BR112012033349A2 (OSRAM) |
| CA (1) | CA2804413A1 (OSRAM) |
| CO (1) | CO6680624A2 (OSRAM) |
| MX (1) | MX2013000107A (OSRAM) |
| RU (1) | RU2578426C2 (OSRAM) |
| WO (1) | WO2012000113A1 (OSRAM) |
| ZA (1) | ZA201209759B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11000545B2 (en) | 2013-03-15 | 2021-05-11 | Cda Research Group, Inc. | Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza |
| US11318089B2 (en) | 2013-03-15 | 2022-05-03 | Cda Research Group, Inc. | Topical copper ion treatments and methods of making topical copper ion treatments for use in various anatomical areas of the body |
| US10398733B2 (en) | 2013-03-15 | 2019-09-03 | Cda Research Group, Inc. | Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body |
| US12318406B2 (en) | 2013-03-15 | 2025-06-03 | Cda Research Group, Inc. | Methods of treatment using topical copper ion formulations |
| FR3004353B1 (fr) * | 2013-04-10 | 2015-05-15 | Fabre Pierre Dermo Cosmetique | Association synergique de l'alanine-glutamine, l'acide hyaluronique et un extrait d'avoine, et son utilisation dans une composition destinee a la cicatrisation et la reparation des lesions cutanees |
| KR101800788B1 (ko) * | 2017-03-31 | 2017-11-27 | 박영오 | 켈로이드 흉터 개선용 화장료 조성물 |
| US10500318B1 (en) * | 2018-07-03 | 2019-12-10 | Temple Therapeutics BV | Dosing regimens for treating hypoxia-associated tissue damage |
| US11193184B2 (en) | 2019-02-22 | 2021-12-07 | Cda Research Group, Inc. | System for use in producing a metal ion suspension and process of using same |
| CN114767590B (zh) * | 2022-04-20 | 2024-03-15 | 上海交通大学医学院附属第九人民医院 | 一种祛疤祛痘印美容液及其制备方法与应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5740409A (en) * | 1980-08-22 | 1982-03-06 | Mitsui Toatsu Chem Inc | Remedy for disease caused by extraordinary propagation of collagen |
| JP2010518172A (ja) * | 2007-02-15 | 2010-05-27 | ユニヴァーシティ オブ サスカチュワン | 腹腔内グルタミンによる術後癒着形成の減少 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6149925A (en) * | 1998-11-05 | 2000-11-21 | Color Access, Inc. | Topical compositions for enhancing glutathione production |
| WO2001014527A1 (en) * | 1999-08-23 | 2001-03-01 | Organogenesis Inc. | Skin care compositions and treatments |
| JP2004532230A (ja) * | 2001-04-30 | 2004-10-21 | アラクノーバ・セラピューティックス・リミテッド | Ｐｐａｒ−ガンマアクチベーターを使用する瘢痕化および関連状態の処置 |
| US20030105025A1 (en) * | 2001-10-31 | 2003-06-05 | Fortuna Haviv | Tri-and tetrapeptides having antiangiogenic activity |
| RU2234963C2 (ru) * | 2002-09-16 | 2004-08-27 | Сибирский государственный медицинский университет | Способ лечения гипертрофических и келоидных кожных рубцов |
| ES2389805T3 (es) * | 2003-09-12 | 2012-10-31 | University Of Colorado | Glutamina para su uso en el tratamiento de una lesión |
| RU2275216C1 (ru) * | 2004-12-08 | 2006-04-27 | Елена Григорьевна Арий | Способ профилактики формирования патологических кожных рубцов |
| PL1940439T3 (pl) * | 2005-08-11 | 2011-04-29 | Univ Saskatchewan | Zmniejszanie tworzenia pooperacyjnych zrostów przez dootrzewnowe podawanie glutaminy |
| WO2007056068A2 (en) * | 2005-11-02 | 2007-05-18 | Bentley Pharmaceuticals, Inc. | Macrocyclic formulations for transmembrane drug delivery |
| CN100372522C (zh) * | 2005-12-02 | 2008-03-05 | 何秋莎 | 护肤品 |
-
2011
- 2011-06-28 JP JP2013516930A patent/JP2013533867A/ja active Pending
- 2011-06-28 WO PCT/CA2011/050396 patent/WO2012000113A1/en not_active Ceased
- 2011-06-28 CA CA2804413A patent/CA2804413A1/en not_active Abandoned
- 2011-06-28 AU AU2011274224A patent/AU2011274224A1/en not_active Abandoned
- 2011-06-28 KR KR1020127034180A patent/KR20130089174A/ko not_active Withdrawn
- 2011-06-28 MX MX2013000107A patent/MX2013000107A/es not_active Application Discontinuation
- 2011-06-28 CN CN201180031168.3A patent/CN103002903B/zh active Active
- 2011-06-28 RU RU2013103507/15A patent/RU2578426C2/ru active
- 2011-06-28 EP EP11800037.1A patent/EP2585090A4/en not_active Withdrawn
- 2011-06-28 US US13/807,378 patent/US20140005116A1/en not_active Abandoned
- 2011-06-28 BR BR112012033349A patent/BR112012033349A2/pt not_active IP Right Cessation
-
2012
- 2012-12-21 ZA ZA2012/09759A patent/ZA201209759B/en unknown
-
2013
- 2013-01-28 CO CO13015329A patent/CO6680624A2/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5740409A (en) * | 1980-08-22 | 1982-03-06 | Mitsui Toatsu Chem Inc | Remedy for disease caused by extraordinary propagation of collagen |
| JP2010518172A (ja) * | 2007-02-15 | 2010-05-27 | ユニヴァーシティ オブ サスカチュワン | 腹腔内グルタミンによる術後癒着形成の減少 |
Non-Patent Citations (3)
| Title |
|---|
| JPN7015001584; 'リザベンカプセル１００ｍｇ' 添付文書 第１０版, 200909 * |
| JPN7015001585; 'ブロメライン軟膏５万単位／ｇ' 添付文書 第６版, 200909 * |
| JPN7015001586; 山口香他: 'トラニラストの皮膚透過性に及ぼす微細化の影響と製剤化' 日本薬学会年会要旨集 , 20070305, ｐ．１２９ * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103002903A (zh) | 2013-03-27 |
| MX2013000107A (es) | 2013-06-03 |
| BR112012033349A2 (pt) | 2016-10-11 |
| EP2585090A1 (en) | 2013-05-01 |
| RU2013103507A (ru) | 2014-08-10 |
| AU2011274224A8 (en) | 2014-09-18 |
| RU2578426C2 (ru) | 2016-03-27 |
| AU2011274224A1 (en) | 2013-01-17 |
| EP2585090A4 (en) | 2014-01-15 |
| CA2804413A1 (en) | 2012-01-05 |
| ZA201209759B (en) | 2014-03-26 |
| US20140005116A1 (en) | 2014-01-02 |
| WO2012000113A1 (en) | 2012-01-05 |
| KR20130089174A (ko) | 2013-08-09 |
| CN103002903B (zh) | 2015-04-22 |
| CO6680624A2 (es) | 2013-05-31 |
| HK1183626A1 (en) | 2014-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013533867A (ja) | ケロイド治療 | |
| US10799622B2 (en) | Reducing post-operative adhesion formation with intraperitoneal glutamine | |
| TWI257307B (en) | Pharmaceutical composition for cardiac tissue repair | |
| US20060293228A1 (en) | Therapeutic compositions and methods using transforming growth factor-beta mimics | |
| AU2023200154A1 (en) | Dosing regimens for treating hypoxia-associated tissue damage | |
| HK1183626B (en) | Keloid treatment | |
| CA2578647A1 (en) | Reducing post-operative adhesion formation with intraperitoneal glutamine | |
| AU2016266102B2 (en) | Reducing post-operative adhesion formation with intraperitoneal glutamine | |
| AU2013204912B2 (en) | Reducing post-operative adhesion formation with intraperitoneal glutamine | |
| HK1120223B (en) | Reducing post-operative adhesion formation with intraperitoneal glutamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140630 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140630 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150610 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150902 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151210 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160530 |